Michael D. Staehler

22.7k citations
255 papers · 16.9k · 12 hit papers · h-index 58

Impact in

Papers in

Michael D. Staehler

241 papers receiving 16.5k citations

Michael D. Staehler's Hit Papers

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 2024 · 99 citations
990+5+11Years since publication5001k1.5k2k

Peers

Michael D. Staehler
Comparison fields: 5 of 124
  • Pulmonary and Respiratory Medicine 11.3k
  • Oncology 1.6k
  • Cancer Research 518
  • Radiology, Nuclear Medicine and Imaging 798
  • Immunology 564
Replace Axel Bex with:
Axel Bex Netherlands
Arnaud Mejean D France
Bradley C. Leibovich United States
Todd Matthew Morgan United States
Axel S. Merseburger Germany
Robert Jeffrey Karnes United States
Michael A.S. Jewett Canada
Christopher J. Kane United States
Maria De Santis Italy
Sandy Srinivas United States
Michael D. Staehler relative to Axel Bex Netherlands Axel Bex's profile →
Citations per field
00.5×1.5×2.1×
Axel Bex · 1×
Citations per year

Countries citing papers authored by Michael D. Staehler

Since Specialization
Citations

This map shows the geographic impact of Michael D. Staehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Staehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Staehler more than expected).

Fields of papers citing papers by Michael D. Staehler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Staehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Staehler. The network helps show where Michael D. Staehler may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael D. Staehler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael D. Staehler Line = papers co-authored together Michael D. Staehler links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 255 papers — load more, or switch the sort, to bring in the rest.

#Work
1
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Hit paper breakdown →
20152286
2
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Hit paper breakdown →
20131585
3
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Hit paper breakdown →
20191114
4
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Hit paper breakdown →
2009936
5
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Hit paper breakdown →
2019826
6
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Hit paper breakdown →
2012686
7
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Hit paper breakdown →
2016598
8
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
Hit paper breakdown →
2015437
9
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Hit paper breakdown →
2009404
10 2009349
11 2008298
12 2014245
13 2010193
14 2019177
15 2017169
16 2013160
17 2011142
18 2017141
19 2016126
20
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Hit paper breakdown →
2023124

About Michael D. Staehler

Michael D. Staehler is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Radiation, Oncology and Surgery, having authored 255 papers that have together received 16.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (187 papers), Prostate Cancer Diagnosis and Treatment (7 papers), Medical Imaging Techniques and Applications (7 papers), Advanced X-ray and CT Imaging (6 papers), Advanced Radiotherapy Techniques (6 papers), Kidney Stones and Urolithiasis Treatments (5 papers), MRI in cancer diagnosis (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (11.3k citations), Oncology (1.6k citations), Cancer Research (518 citations), Radiology, Nuclear Medicine and Imaging (798 citations) and Immunology (564 citations). Michael D. Staehler has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Axel Bex, Börje Ljungberg, Saeed Dabestani, Thomas B. L. Lam, Lorenzo SO Marconi, Thomas B. Powles, Karim Bensalah, Alessandro Volpe, Markus Antonius Kuczyk and Milan Hora. Their work appears in journals such as European Urology, Annals of Oncology, The Journal of Urology, Clinical Genitourinary Cancer and British Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact